Showing results (151-160 of 182) with videos related to
Sort By:
Pageof 19
The Oncologist|February 8, 2017
Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center ExperienceJasmeet C Singh, Anita Mamtani, Andrea Barrio, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2003
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741Marc L Citron, Donald A Berry, Constance Cirrincione, et al.Breast Cancer Research and Treatment|May 19, 2015
Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial)Kathryn J Ruddy, Hao Guo, William Barry, et al.International Journal of Radiation Oncology, Biology, Physics|November 19, 2023
Direct Tumor Irradiation Potentiates Adoptive NK Cell Targeting Against Parental and Stemlike Cancer in Human Liver Cancer ModelsTung Nguyen Thanh Uong, Meesun Yoon, Ik-Joo Chung, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2026
Benralizumab relieves Eosinophil-Related Cutaneous Adverse Events from Cancer Therapy: A Nonrandomized Phase 2 TrialMario E Lacouture, Alexander Pan, Tara Maier, et al.NPJ Breast Cancer|November 30, 2022
Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT)Tal Sella, Yue Zheng, Nabihah Tayob, et al.Breast Cancer Research and Treatment|January 5, 2021
Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart functionKatia Khoury, Filipa Lynce, Ana Barac, et al.Cancer Research|August 5, 2016
Exercise and Prognosis on the Basis of Clinicopathologic and Molecular Features in Early-Stage Breast Cancer: The LACE and Pathways StudiesLee W Jones, Marilyn L Kwan, Erin Weltzien, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2004
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004Eric P Winer, Clifford Hudis, Harold J Burstein, et al.Cancer Immunology Research|September 3, 2016
Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after ImmunotherapyDavid B Page, Jianda Yuan, David Redmond, et al.Pageof 19